Gilead Sciences Inc

Gilead Sciences Inc
Gilead Sciences Inc
Type: Company
Name: Gilead Sciences Inc
First reported 17 hours ago - Updated 5 hours ago - 2 reports
Spirit Airlines Inc
Spirit Airlines Inc

Cramer's Top Stock Picks: SAVE GILD BMY HTA TSLA

NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Monday's "Mad Money" on CNBC:SAVE data by YCharts Spirit Airlines GILD data by YCharts Gilead Sciences HTA data by YChartsHealthcare Trust of America ... [Published Freeport Journal - 17 hours ago]
First reported 9 hours ago - Updated 8 hours ago - 4 reports

Gilead Hepatitis C Drug Sofosbuvir Granted Accelerated Review in

Gilead Sciences Inc. ( GILD ) said the marketing authorization application for its new hepatitis C drug has been validated by the European Medicines Agency and granted accelerated assessment.Gilead is also seeking U.S. Food and Drug Administration approval ... [Published Nasdaq - 8 hours ago]
First reported 10 hours ago - Updated 10 hours ago - 1 reports
Gilead Sciences Inc
Gilead Sciences Inc

Gilead Sciences Stock Rating Reaffirmed by JPMorgan Chase (GILD)

JPMorgan Chase reiterated their overweight rating on shares of Gilead Sciences (NASDAQ: GILD) in a research report sent to investors on Friday morning, ARN reports. The firm currently has a $80.00 price target on the stock.Shares of Gilead Sciences ( ... [Published Mideast Time - 10 hours ago]
First reported 12 hours ago - Updated 11 hours ago - 2 reports
FDA Food & Drug Administration
FDA Food & Drug Administration

2013 FDA Drug Approval Calendar

Home » Blogs » BOSTON (TheStreet) -- Gilead Sciences and Amarin highlight the updated list of biotech and pharmaceutical companies with FDA drug approval decisions expected for the remainder of 2013.Related Biotechnology, Pharmaceutical and Healthcare ... [Published BioPortfolio - 11 hours ago]
First reported May 21 2013 - Updated 14 hours ago - 1 reports

Cancer Genetics Reports First Quarter 2013 Financial Results

Cancer Genetics, Inc. ("CGI") is a company in the diagnosis and disease management for the most complex and difficult-to-treat cancers, including hematologic, urogenital, and gynecological malignancies. In a release on May 15, the Company noted that CGI's ... [Published Individual.com - May 21 2013]
Entities: Genomics, Cancer, Genetics
First reported May 20 2013 - Updated 14 hours ago - 1 reports
Motley Fool
Motley Fool

3 Upgrades on Friday Worth Noting

Brian is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.While the market continued its miraculous run on Friday with gains, the following three stocks saw even greater upside ... [Published Motley Fool - May 20 2013]
First reported 15 hours ago - Updated 14 hours ago - 1 reports
Jim Cramer
Jim Cramer

Cramer: Buy Gilead Sciences, General Mills, Genworth Financial, and These 2 Stocks

Jim Cramer made the following calls on May 20th, 2013. What do you think about his picks?Gilead Sciences  ( NASDAQ:GILD ): Jim Cramer ranked this stock a  Buy . Cramer previously ranked this stock a Buy on May 16, 2013. The stock’s 52-week high is $55.16, ... [Published Wall St. Cheat Sheet - 15 hours ago]
First reported 17 hours ago - Updated 17 hours ago - 1 reports

News Behind Insider Trading: American International Group, First Solar, Gilead Sciences, J.C. Penney, U.S...

News Behind Insider Trading: American International Group, First Solar, Gilead Sciences, J.C. Penney, U.S. Bancorp, and Chesa...HONG KONG, May 21, 2013 /PRNewswire/ -- Insiderslab.com releases insider trading activities report in US market. Today's reports ... [Published ADVFN India - 17 hours ago]
First reported May 20 2013 - Updated May 21 2013 - 1 reports

Royalty Pharma Raises Takeover Bid for Elan

LONDON--U.S. pharmaceutical investor Royalty Pharma on Monday raised its multibillion-dollar takeover bid for Dublin-based Elan Corp. (DRX.DB, ELN) by 11% to $12.50 a share in cash, adding pressure on Elan as it moves to rebuild its business and secure ... [Published 4 Traders - May 20 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports

Healthcare Review: Peregrine Pharmaceuticals, XenoPort,Gilead Sciences, Affymax, ACADIA Pharmaceuticals

U.S. stocks were little changed on Monday as acquisition activity gave support but investors were reluctant to rush into the market with indexes hovering around record levels. Deals including Yahoo's $1.1 billion bid for Tumblr indicate that companies ... [Published BioMedReports - May 20 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports

Gilead Sciences' Management Presents at the 2013 UBS Global Healthcare Conference (Transcript)

Matthew Roden - UBSGood morning, everyone. My name is Matt Roden. I'm one of the biotech analysts here at UBS and I'd like to thank everyone for attending our new UBS Global Healthcare Conference. I'm pleased and privileged to introduce here Gilead Sciences ... [Published Seeking Alpha - May 20 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports

GILEAD SCIENCES - New HIV + HCV Products to Sustain the Growth Trajectory - new market research report

Initial sales of newly added HIV products - Complera/ Eviplera (L, truvada + rilpivirine), Stribild (L in US, R in EU, truvada+ cobicistat+ elvitegravir) along with growth in other marketed products contributed to the impressive 4Q12/FY13 results of ... [Published TransWorldNews - May 20 2013]

Quotes

"At the moment, you have all these hoops ... Clinics have a limited capacity and waiting times for an appointment can be 3-6 months."
Oral drug 'to revolutionise' hep C treatment [Published Australian Doctor - 2 hours ago]
...efavirenz, emtricitabine and tenofovir Disoproxil fumarate tablets, 600 mg/200 mg/300 mgAgency Reviews Patent Application Approval Request for "Methods for Treatment of HIV and Other Infections Using a T Cell Or Viral Activator and Anti-Retroviral Combination Therapy" New Superiority Trial Showed LIVALO® pitavastatin 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus...
Tentative approval of lamivudine and tenofovir disoproxil fumarate Tablets, 300 mg/300 mg [Published AEGIS - 4 hours ago]
...PHARMACY gTLD in a stable and secure manner. $ "Passing this hurdle in the PHARMACY application process is a significant success in NABP's initiative to establish a safe online space that will benefit patients and the health care community around the world. With the online distribution of counterfeit and substandard medications posing a growing threat to consumers, NABP is extremely pleased to move forward with its plans for the PHARMACY gTLD" states NABP President Karen M Ryle
NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation [Published Digital Journal - 8 hours ago]
...threat to consumers, NABP is extremely pleased to move forward with its plans for the PHARMACY gTLD," states NABP President Karen M Ryle, MS, RPh. "By distinguishing .PHARMACY as a domain space exclusively for appropriately licensed, legitimate Internet pharmacies operating in compliance with international pharmacy standards, NABP aims to protect the global public health from dangers of substandard drugs distributed by rogue online sellers."
NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation [Published Sys-Con Australia - 8 hours ago]

More Content

All (1148) | News (731) | Reports (44) | Blogs (146) | Audio/Video (4) | Fact Sheets (7) | Press Releases (216)
sort by: Date | Relevance
European Medicines Agency bevestigt marktaanvra... [Published Business Wire Communications News - 40 mins ago]
European Medicines Agency bevestigt marktaanvra... [Published Business Wire Health News - 40 mins ago]
Oral drug 'to revolutionise' hep C treatment [Published Australian Doctor - 2 hours ago]
Tentative approval of lamivudine and tenofovir ... [Published AEGIS - 4 hours ago]
COLORADO: Boulder Groups Honor More Than 150 Lo... [Published AEGIS - 4 hours ago]
COLORADO: Peer to Peer: Teens Work to Educate P... [Published AEGIS - 4 hours ago]
PENNSYLVANIA: Area Residents Screened for Hepat... [Published AEGIS - 4 hours ago]
JAMAICA: AIDS Awareness Workshop Organised for ... [Published AEGIS - 4 hours ago]
NABP's .PHARMACY Proposal Passes Initial ICANN ... [Published Digital Journal - 8 hours ago]
NABP's .PHARMACY Proposal Passes Initial ICANN ... [Published Sys-Con Australia - 8 hours ago]
Gilead Hepatitis C Drug Sofosbuvir Granted Acce... [Published Nasdaq - 8 hours ago]
EMA Validates Gilead's Marketing Application Fo... [Published RTTNews.com - 8 hours ago]
GILEAD SCIENCES, INC.: Gilead Hepatitis C Drug ... [Published 4 Traders - 8 hours ago]
EMA Approves MAA for Gilead's (GILD) Sofosbuvir [Published Street Insider - 9 hours ago]
European Medicines Agency Validates Gilead’s Ma... [Published Business Wire - 9 hours ago]
European Medicines Agency Validates Gilead’s Ma... [Published Business Wire Communications News - 10 hours ago]
European Medicines Agency Validates Gilead’s Ma... [Published Business Wire Health News - 10 hours ago]
Gilead Sciences Stock Rating Reaffirmed by JPMo... [Published Mideast Time - 10 hours ago]
2013 FDA Drug Approval Calendar [Published BioPortfolio - 11 hours ago]
Top 10 Biotech CEO Pay Packages of 2012 [Published FierceBiotech - 11 hours ago]
Ranbaxy Laboratories gets tentative approval fo... [Published Pharmaceutical Technology - 12 hours ago]
2013 FDA Drug Approval Calendar [Published Oncology Business Review - 12 hours ago]
Insiders And Funds Are Bullish On These 3 Small... [Published Seeking Alpha - 13 hours ago]
Anti-AIDS pill makes cash sense for some gays: ... [Published Yahoo! Singapore - 13 hours ago]
ConsultingMD Receives $10 Mln from Venrock [Published PE Hub News - 15 hours ago]
Cramer: Buy Gilead Sciences, General Mills, Gen... [Published Wall St. Cheat Sheet - 15 hours ago]
Cramer: Buy Gilead Sciences, General Mills, Gen... [Published Wall St. Cheat Sheet - 15 hours ago]
Will Influenza A H7N9 Generate Opportunities Fo... [Published Seeking Alpha - 16 hours ago]
News Behind Insider Trading: American Internati... [Published ADVFN India - 17 hours ago]
News Behind Insider Trading: American Internati... [Published Financial Services - 17 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
Jim Cramer, Robin Washington, John C Martin, [more]
  •  
YM Biosciences Inc, New York Stock Exchange, IBT, [more]
  •  
FDA Food & Drug Administration, European Medicines Agency, AIDS Healthcare Foundation, [more]
  •  
HIV/AIDS, Sofosbuvir, Drugs, [more]
  •  
Stribild, Viread, Truvada, [more]
  •  
Foster City (United States), Bristol, San Francisco (United States), [more]
  •  
United States, Ireland, Japan, [more]
  •  
Medicine, Medication, Biology, [more]
  •  
Pharma & Biotech, Banking & Financial Services, Health, [more]
Business Wire Health News, MarketIntelligenceCenter.com, Wall St. Cheat Sheet, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cramer: Buy Gilead Sciences, General Mills, Gen... [Published Wall St. Cheat Sheet - 15 hours ago]
Jim Cramer made the following calls on May 20th, 2013. What do you think about his picks?Gilead Sciences  ( NASDAQ:GILD ): Jim Cramer ranked this stock a  Buy . Cramer previously ranked this stock a Buy on May 16, 2013. The stock’s 52-week high is $55.16, ...
Cramer: Buy Gilead Sciences, General Mills, Gen... [Published Wall St. Cheat Sheet - 15 hours ago]
Jim Cramer made the following calls on May 20th, 2013. What do you think about his picks? Gilead Sciences  ( NASDAQ:GILD ): Jim Cramer ranked this stock a  Buy . Cramer previously ranked this stock a Buy on May 16, 2013. The stock’s 52-week high ...
Staples Launches Sports & Art Photo Gallery and... [Published Wall St. Cheat Sheet - May 17 2013]
Staples ( NASDAQ:SPLS ): Current price $14.51 Staples has introduced its new Sports & Art Photo Gallery, which gives consumers quick, affordable, and beautiful over-sized prints, through which to facilitate finding gifts or home design. The new digital ...
Jim Cramer: Buy Gilead Sciences, Kinder Morgan,... [Published Wall St. Cheat Sheet - May 17 2013]
Jim Cramer made the following calls on May 16th, 2013. What do you think about his picks?Gilead Sciences Inc.  ( NASDAQ:GILD ): Jim Cramer ranked this stock a  Buy . Cramer previously ranked this stock a Buy on May 14, 2013. The stock’s 52-week high is ...
Jim Cramer: Buy Gilead Sciences, Kinder Morgan,... [Published Wall St. Cheat Sheet - May 17 2013]
Jim Cramer made the following calls on May 16th, 2013. What do you think about his picks? Gilead Sciences Inc.  ( NASDAQ:GILD ): Jim Cramer ranked this stock a  Buy . Cramer previously ranked this stock a Buy on May 14, 2013. The stock’s 52-week ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
John F. Milligan, PhD, President and Chief Oper... [Published BIO Channel - YouTube - Feb 26 2013]
The Top Ten Stocks for Monday, November 12 [Published Bloomberg - YouTube - Feb 26 2013]
Fireside Chat With John F. Milligan, PhD, Presi... [Published BIO Channel - YouTube - Feb 26 2013]
Fireside Chat With John F. Milligan, PhD, Presi... [Published BIO Channel - YouTube - Feb 19 2013]
1

Press Releases

sort by: Date | Relevance
European Medicines Agency bevestigt marktaanvra... [Published Business Wire Communications News - 40 mins ago]
European Medicines Agency bevestigt marktaanvra... [Published Business Wire Health News - 40 mins ago]
European Medicines Agency Validates Gilead’s Ma... [Published Business Wire - 9 hours ago]
European Medicines Agency Validates Gilead’s Ma... [Published Business Wire Communications News - 10 hours ago]
European Medicines Agency Validates Gilead’s Ma... [Published Business Wire Health News - 10 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.